ABT-751 | 141449-99-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ABT-751
• 英文别名: N-[2-[(4-Hydroxyphenyl)amino]phenyl]-4-methoxybenzenesulfonamide；N-[2-(4-hydroxyanilino)phenyl]-4-methoxybenzenesulfonamide
• CAS: 141449-99-2
• 化学式: C₁₉H₁₈N₂O₄S
• 分子量: 370.429
• InChiKey: PKXSRIFYZWAWGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  96
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Predictive baseline biomarkers for use of vascular disrupting agents
  申请人：BIONOMICS LIMITED

  公开号：US10520508B2

  公开（公告）日：2019-12-31

  The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

  本公开涉及可预测患者对血管破坏剂治疗反应的生物标志物铁蛋白和IL-8。特别是，本公开涉及可预测癌症患者对血管破坏剂治疗反应的生物标记物，以及用血管破坏剂治疗癌症患者的方法。
• Sulfonamide derivatives
  申请人：Eisai Co., Ltd.

  公开号：EP0472053B1

  公开（公告）日：1998-06-17
• PREDICTIVE BASELINE BIOMARKERS FOR USE OF VASCULAR DISRUPTING AGENTS
  申请人：BIONOMICS LIMITED

  公开号：US20180196056A1

  公开（公告）日：2018-07-12

  The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
• US5250549A
  申请人：——

  公开号：US5250549A

  公开（公告）日：1993-10-05
• US5292758A
  申请人：——

  公开号：US5292758A

  公开（公告）日：1994-03-08